Changes of Regulatory T and B Cells in Patients with Papillary Thyroid Carcinoma after ¹³¹I Radioablation: A Preliminary Study

Table 1

Clinical data of patients and healthy donors.

Variable	Patients		Healthy donors
	Pre-T	Post-T
Gender (female/male)	20/10		11/9
Age (median, range, yr)	45 (26−70)		43 (22−63)
Free T3 (normal: 2.8–7.1 pmoL/L)	1.38±0.77	5.31±2.87	4.54±1.60
Free T4 (normal: 12.0–22.0 pmoL/L)	2.60±0.85	19.1±13.1	16.72±2.67
TSH (normal: 0.27–4.2 μIU/mL)	84.56±17.11	2.39±2.73	2.14±1.13
Tg (normal: 1.4–78 ng/mL)	13.32±14.2	0.73±0.65	22.72±17.46
Anti-Tg (normal: <115 IU/mL)	15.36±4.72	12.94±4.10	20.82±11.47
Anti-TPO (normal: <34 IU/mL)	10.99±5.45	10.00±5.27	8.86±5.42

For PTC patients, the blood samples of pretreatment and aftertreatment were collected under different conditions. Patients were inhibited to take levothyroxine sodium tablets or similar euthyrox drugs for at least 3 weeks before the ¹³¹I ablation. One month posttreatment, patients do the blood tests with routine suppressive therapy of thyroid hormone.